While this pembrolizumab-based regimen is promising and much needed in this patient population, one should remain cognizant of its high costs and the subsequent impact this may have on patients and ...

Patients in the pembrolizumab-olaparib arm had clinically meaningful improvements in PFS over patients in the control arm.

Findings from a phase 2 trial published in JTO Clinical and Research Reports suggest that pembrolizumab (Keytruda) plus ...

followed by either pembrolizumab (200mg IV Q3W for 15 cycles) plus standard of care radiotherapy with cisplatin (100mg/m 2 IV Q3W for 3 cycles) as adjuvant therapy, following surgery for high-risk ...

In patients with advanced or recurrent endometrial cancer (EC) with previous exposure to carboplatin and paclitaxel (PT), ...

Based on the first interim analysis of the trial, the FDA approved pembrolizumab plus CCRT for the treatment of patients with FIGO 2014 stage III-IVA cervical cancer. KEYNOTE A-18 was a randomized ...

Updated data "reinforce enfortumab vedotin and pembrolizumab as the new standard of care in frontline urothelial cancer,” said Thomas Powles, MD, MBBS.

Opens in a new tab or window The government's next list of drugs targeted for price negotiation could include the blockbuster immunotherapy pembrolizumab ... estrogen receptor degrader ...